COVID-19 vaccine safety and immunogenicity in patients with cold agglutinin disease receiving concomitant sutimlimab
© 2024 SANOFI. American Journal of Hematology published by Wiley Periodicals LLC..
Patients with cold agglutinin disease (CAD) are more vulnerable to infectious agents, thus the COVID-19 pandemic has posed a particular risk to this population. Sutimlimab Phase 3 studies CARDINAL and CADENZA spanned the period before and during the pandemic; investigators were advised to vaccinate enrolled patients without stopping treatment. Of 61 completers from both studies, 47 received ≥1 dose of a COVID-19 vaccine. In the immunogenicity analysis (n = 27) all patients developed an immune response post-COVID-19 vaccination, with detectable immunoglobulin G anti-spike antibodies. Analysis of six patients with booster vaccinations demonstrated increased immune responses pre- to post-booster. COVID-19 vaccines were well tolerated in patients with CAD receiving sutimlimab treatment, and no signs of hemolytic exacerbations were observed post-vaccination.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:99 |
|---|---|
| Enthalten in: |
American journal of hematology - 99(2024), 4 vom: 19. März, Seite 789-791 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Fattizzo, Bruno [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antibodies, Monoclonal, Humanized |
|---|
| Anmerkungen: |
Date Completed 19.03.2024 Date Revised 19.03.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1002/ajh.27234 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM368756440 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM368756440 | ||
| 003 | DE-627 | ||
| 005 | 20240319232746.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240222s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1002/ajh.27234 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1336.xml |
| 035 | |a (DE-627)NLM368756440 | ||
| 035 | |a (NLM)38385639 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Fattizzo, Bruno |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a COVID-19 vaccine safety and immunogenicity in patients with cold agglutinin disease receiving concomitant sutimlimab |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 19.03.2024 | ||
| 500 | |a Date Revised 19.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2024 SANOFI. American Journal of Hematology published by Wiley Periodicals LLC. | ||
| 520 | |a Patients with cold agglutinin disease (CAD) are more vulnerable to infectious agents, thus the COVID-19 pandemic has posed a particular risk to this population. Sutimlimab Phase 3 studies CARDINAL and CADENZA spanned the period before and during the pandemic; investigators were advised to vaccinate enrolled patients without stopping treatment. Of 61 completers from both studies, 47 received ≥1 dose of a COVID-19 vaccine. In the immunogenicity analysis (n = 27) all patients developed an immune response post-COVID-19 vaccination, with detectable immunoglobulin G anti-spike antibodies. Analysis of six patients with booster vaccinations demonstrated increased immune responses pre- to post-booster. COVID-19 vaccines were well tolerated in patients with CAD receiving sutimlimab treatment, and no signs of hemolytic exacerbations were observed post-vaccination | ||
| 650 | 4 | |a Letter | |
| 650 | 7 | |a COVID-19 Vaccines |2 NLM | |
| 650 | 7 | |a sutimlimab |2 NLM | |
| 650 | 7 | |a GNWE7KJ995 |2 NLM | |
| 650 | 7 | |a Antibodies, Viral |2 NLM | |
| 650 | 7 | |a Antibodies, Monoclonal, Humanized |2 NLM | |
| 700 | 1 | |a Röth, Alexander |e verfasserin |4 aut | |
| 700 | 1 | |a Broome, Catherine M |e verfasserin |4 aut | |
| 700 | 1 | |a Khan, Umer |e verfasserin |4 aut | |
| 700 | 1 | |a Wardęcki, Marek |e verfasserin |4 aut | |
| 700 | 1 | |a Cordoba, Matias |e verfasserin |4 aut | |
| 700 | 1 | |a Barcellini, Wilma |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t American journal of hematology |d 1993 |g 99(2024), 4 vom: 19. März, Seite 789-791 |w (DE-627)NLM000124354 |x 1096-8652 |7 nnns |
| 773 | 1 | 8 | |g volume:99 |g year:2024 |g number:4 |g day:19 |g month:03 |g pages:789-791 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1002/ajh.27234 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 99 |j 2024 |e 4 |b 19 |c 03 |h 789-791 | ||